Journal of the National Comprehensive Cancer Network · 2024 · 756 citations · 120 references
MedicineMolecular MedicineOncologyMolecular OncologyPrecision MedicineThoracic OncologyBiomarker-guided Therapy SelectionCancer Precision MedicineCancer StagingCancer Treatment PlanningLung CancerLung MetastasisClinical Practice Guidelines ImplementationLung Cancer StagingLung Metastases ManagementNon-small Cell Lung Cancer Adjuvant TherapyNon-small Cell Lung Cancer TherapyNon-small Cell Lung Cancer Treatment
The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Non-Small Cell Lung Cancer (NSCLC) provide recommendations for the treatment of patients with NSCLC, including diagnosis, primary disease management, surveillance for relapse, and subsequent treatment. The panel has updated the list of recommended targeted therapies based on recent FDA approvals and clinical data. This selection from the NCCN Guidelines for NSCLC focuses on treatment recommendations for advanced or metastatic NSCLC with actionable molecular biomarkers.
120
Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
H. Borghaei, L. Paz-Ares, Leora Horn et al. · New England Journal of Medicine · 2015 · 9.5K citations · Full text
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
Tony Mok, Yi‐Long Wu, Sumitra Thongprasert et al. · New England Journal of Medicine · 2009 · 8.2K citations · Full text
Medicine, Oncology, Pharmacology +13
Rafael Rosell, Enric Carcereny, Radj Gervais et al. · The Lancet Oncology · 2012 · 5.5K citations · Full text
Medicine, Oncology, Pharmacology +12